{
  "eval_id": "S18",
  "eval_file": "evals/single/S18.json",
  "timestamp": "2025-09-18T17:14:10.755342+00:00",
  "model": "gpt-4.1",
  "temperature": 0.6,
  "rep_input": "Patient HR+/HER2- progressed after CDK4/6; what key label-based caveats should I discuss?",
  "model_output": "After progression on CDK4/6 in HR+/HER2- disease, I focus on what’s supported in the EMA label for each agent—mainly prior treatments, endocrine sensitivity, and any contraindications. If you have a specific drug in mind, please clarify so I can address label-based considerations."
}